Contrasting Aphria (APHA) & Its Rivals

Aphria (NASDAQ: APHA) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its rivals? We will compare Aphria to related companies based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, risk, valuation and earnings.

Risk and Volatility

Aphria has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Aphria’s rivals have a beta of 2.56, indicating that their average share price is 156% more volatile than the S&P 500.

Institutional & Insider Ownership

11.3% of Aphria shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Aphria and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aphria 0 0 2 0 3.00
Aphria Competitors 136 361 413 14 2.33

Aphria currently has a consensus target price of $9.88, indicating a potential upside of 112.37%. As a group, “Medicinals & botanicals” companies have a potential upside of 97.53%. Given Aphria’s stronger consensus rating and higher probable upside, research analysts clearly believe Aphria is more favorable than its rivals.

Valuation & Earnings

This table compares Aphria and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aphria $405.96 million -$63.21 million -77.50
Aphria Competitors $218.50 million -$99.79 million 1.73

Aphria has higher revenue and earnings than its rivals. Aphria is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Aphria and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aphria -14.89% -2.05% -1.47%
Aphria Competitors -163.69% -267.59% -46.37%


Aphria beats its rivals on 8 of the 13 factors compared.

Aphria Company Profile

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with's FREE daily email newsletter.